



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/612,338	07/03/2003	Hans R. Brunner	7571/80526	3790
66991 7590 07/16/2007 LAW OFFICE OF MICHAEL A. SANZO, LLC 15400 CALHOUN DR. SUITE 125 ROCKVILLE, MD 20855				
			EXAMINER GEMBEH, SHIRLEY V	
			ART UNIT 1614	PAPER NUMBER
			MAIL DATE 07/16/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/612,338	Applicant(s) BRUNNER, HANS R.	
	Examiner Shirley V. Gembeh	Art Unit 1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 April 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 12-17 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 12-17 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The response filed **4/17/07** presents remarks and arguments to the office action mailed **1/17/07**. Applicants' request for reconsideration of the rejection of claims in the last office action has been considered.

Applicants' arguments, filed, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The specie election of celecoxib as the COX-2 inhibitor and ifetroban as the thromboxane A2 receptor antagonist is acknowledged and applied to the rejections below.

Status of claims

Claims 12-17 are pending in this office action.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 12-17 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter

Art Unit: 1614

which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Nowhere in the specification is there a mention of "by all patients" as amended in instant claim 12 taking into consideration, the population of patients. For example, by all patients is inclusive of patients outside the claim limitation, such population includes patients with HIV, Alzheimer's, Chron's disease. The claims are only limited to the population for the treatment of arterial or venous thrombosis, angina, transient ischemic attack, hypertension, headache, muscle or post surgical pain and arthritis.

Claims 13-17 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating arterial or venous thrombosis, angina, transient ischemic attack and hypertension for cardiovascular condition and inflammation associated with arthritis, does not reasonably provide enablement for the broad treatment of inflammation and or cardiovascular conditions. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in Ex parte Forman, 230 USPQ 546 (BPAI 1986) and reiterated by the Court of Appeals in In re Wands, 8 USPQ2nd 1400 at 1404 (CAFC 1988). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2)

Art Unit: 1614

the amount or direction presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The Board also stated that although the level of skill in molecular biology is high, the results of experiments in genetic engineering are unpredictable. While all of these factors are considered, a sufficient amount for a prima facie case are discussed below.

Nature of the invention state of the prior art, relative skill of those in the art and the predictability of the art.

The nature of the invention is to a therapeutic package for dispensing to a patient comprising of celecoxib and ifetroban in a container with a labeling instruction for the treatment of inflammation and cardiovascular condition.

The state of the prior art as evident by University of Illinois Medical Center teaches Cox-2 inhibitors increase the risk of thrombotic events (see underlined sec pg. 1) and that health care providers should avoid the use of in patients with cardiovascular disease (see pg 2, underlined sec.), that the cardiovascular safety are of concerns.

As stated, however, claims 13-17 recite that any or the wide variation of inflammatory condition and cardiovascular conditions or disease are intended (see for example as evident by American Heart Association), the various cardiovascular conditions. With regards to inflammation it is process that can take place in virtually any part of the body. There is a vast range of forms that it can take, causes for the problem, and biochemical pathways that mediate the inflammatory reaction. There is no common mechanism by which all, or even most, inflammations arise. Mediators include

Art Unit: 1614

bradykinin, serotonin, C3a, C5a, histamine, leukotrienes, cytokines, and many, many others. Accordingly, treatments for diseases associated with inflammation are normally tailored to the particular type of inflammation present, as there is no, and there can be no "magic bullet" against all inflammation related diseases generally.

The nature of the invention is very broad, and the relative skill of those in the art is generally that of a Ph.D. or M.D. with expertise in the field of cardiovascular and inflammatory diseases. Each particular cardiovascular condition or inflammatory disease has its own specific characteristics and etiology. The unpredictability observed with single agent therapy is compounded when a combination of agents is employed. The broad recitation "treating a cardiovascular or inflammatory disease" is inclusive of many conditions that presently have no established successful therapies.

It is clear the art to which the present invention relates is highly unpredictable and unreliable with respect to conclusions drawn from laboratory data extrapolated to clinical efficacy.

The breadth of the claims

The claims are very broad and inclusive of a wide representation of cardiovascular condition or inflammatory disease.

The amount of direction or guidance provided and the presence or absence of working examples

There are no working examples to any specific inflammatory or cardiovascular disease.

Maintained Claim Rejections - 35 USC § 102

Applicant argues that the teachings of the prior art is different from the instantly claimed invention in that the prior art only recognizes traditional NSAIDs inhibit COX-1 and that the beneficial effect of COX-1 inhibition is lost when specific COX-2 are used and fails to recognize that upsetting the normal balance between COX-1 and COX-2 creates cardiovascular problems (see remarks pg. 5).

In response, Applicant is traversing the mechanism, which is not in the claim recitation all the limitations of the instantly claimed invention is taught by the prior art. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., mechanism of action) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Next, with regards to labeling is not new, every single pharmaceutical drug gives labeling on how to use, dosage for different age groups, appropriate instructions for what conditions the drug is to be used for, how to take and the adverse effects of the drug. Thus not a novel concept because the claims recites a COX-2 inhibitor celecoxib and a thromboxane A2 receptor antagonist ifetroban, labeling in a package will not change the composition nor its properties.

Applicant's arguments have been fully considered but they are not persuasive, for the above reasons, the rejection is maintained and repeated.

Art Unit: 1614

Claims 12-17 are rejected under 35 U.S.C. 102(e) as being anticipated by Scolnick et al. US 2002/0016342 A1.

Scolnick et al. teach the COX-2 inhibitor as celecoxib and the thromboxane A2 antagonist as ifetroban as in claim 12 in part wherein the composition is used to treat inflammation, (see 0014), as in claim 13, angina, a transient ischemic attack-stroke (see para. 0015) as in claim 14, pain associated with headache, muscle pain or post surgical (see para 0014) as in the instant claim 15, arthritis (see para. 0011) as in claim 16. The celecoxib is present in an amount of 0.001-50 mg/kg. (Average weight of humans are about 70 kg if the composition is 0.5 then 0.5×70 equals 35 mg which is within the claim limitation) as in claim 17.

With regards to the printed matter in claim 12 and dependent claims 13-17 as addressed above

The printed matter on a label or package insert of a kit or container does not lend patentable weight as a limitation of the claimed product, composition, or article of manufacture, absent a functional relationship between the label or package insert of a kit and the product, composition, or article of manufacture of a kit or container.

See *In re Haller* 73 USPQ 403 (CCPA 1947), where it is held that application of printed matter to old article cannot render the article patentable. In the opinion text of *In re Haller*, it is stated that: Whether the statement of intended use appears merely in the claim or in label on the product is immaterial so far as the question of Patentability is concerned . . . In accordance with the patent statutes, an article or composition of matter, in order to be patentable, must not only be useful and involve invention, but must

Art Unit: 1614

also be new. If there is no novelty in an article or composition itself, then a patent cannot be properly granted on the article or composition, regardless of the use for which it is intended. The difficulty is not that there can never be invention in discovering a new process involving the use of an old article, but that the statutes make no provision for patenting of an article or composition which is not, in and of itself, new.

Also see *In re Venezia* 189 USPQ 49 (CCPA 1976), where kits are drawn to the structural attributes of interrelated component parts and not to activities that may or may not occur. Further, *In re Miller* 164 USPQ 46 (CCPA 1969) and *In re Gulak* (CAFC) 217 USPQ 401 relate to a mathematical device and to a measuring cup respectively as well as *In re Ngai*, 70 USPQ2d 1862 (CAFC 2004). In each of these cases, the printed matter is considered a patentable distinction because the function of the device depends upon the printed matter itself, which is a patentable distinction because the function of the device depends upon the printed matter itself, which is a part of the substrate; without the printed indicia or numbers, the substrates lose their function. Such is not the case with the instantly claimed articles or kits. The claimed articles of the kit remain fully functional absent the labeling or printed instructions for use.

Thus the instructions for use included in a kit or article manufacture constitute an "intended use" for that kit or article of manufacture. Intended use does not impart patentable weight to a product. See MPEP 2111.03: Intended use recitations and other types of functional language cannot be entirely disregarded. However, in apparatus, article and composition claims, intended use must result in a structural difference

Art Unit: 1614

between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. *In re Casey*, 370 F.2d 576, 152 USPQ 235 (CCPA 1967); *In re Otto*, 312 F.2d 937, 938, 136 USPQ 458, 459 (CCPA 1963).

In the instant case, the kit claims are drawn to an old article or composition, which further comprises labeling instructions. The intended use, which is recited on the label or package of the insert, lacks a function relationship because the insert or label does not physically or chemically affect the chemical nature within the article of manufacture, and furthermore, the old article or old composition of the kit can still be used by the skilled artisan for other purposes. Therefore the old article or composition which are comprised with the claimed kit are unpatentable over the prior art, because they function equally effectively with or without the labeling, and accordingly no functional relationship exists between the instructions for use and the composition.

Thus the claims are addressed as being drawn to an article of manufacture comprising an old composition of a kit and a package insert, the instructions on the insert bearing no patentable weight with regard to double patenting, 102 and 103 rejections.

No claim is allowed.

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembah whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SVG
6/26/07


ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER